Jefferies Financial Group Inc. Takes $890,000 Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Jefferies Financial Group Inc. acquired a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 24,600 shares of the specialty pharmaceutical company's stock, valued at approximately $890,000.

Other large investors have also made changes to their positions in the company. Vanguard Group Inc. lifted its position in Supernus Pharmaceuticals by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 6,150,759 shares of the specialty pharmaceutical company's stock worth $222,411,000 after buying an additional 22,852 shares during the period. Geode Capital Management LLC raised its stake in Supernus Pharmaceuticals by 1.9% during the fourth quarter. Geode Capital Management LLC now owns 1,510,568 shares of the specialty pharmaceutical company's stock worth $54,633,000 after purchasing an additional 28,517 shares during the period. American Century Companies Inc. boosted its holdings in shares of Supernus Pharmaceuticals by 9.2% in the 4th quarter. American Century Companies Inc. now owns 1,140,705 shares of the specialty pharmaceutical company's stock valued at $41,248,000 after purchasing an additional 95,777 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Supernus Pharmaceuticals by 5.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 753,363 shares of the specialty pharmaceutical company's stock valued at $27,242,000 after buying an additional 40,968 shares during the period. Finally, Northern Trust Corp increased its holdings in shares of Supernus Pharmaceuticals by 18.3% during the 4th quarter. Northern Trust Corp now owns 717,161 shares of the specialty pharmaceutical company's stock worth $25,933,000 after buying an additional 110,867 shares during the last quarter.

Supernus Pharmaceuticals Price Performance

NASDAQ SUPN traded up $0.11 during mid-day trading on Friday, hitting $31.79. The company's stock had a trading volume of 750,724 shares, compared to its average volume of 482,619. Supernus Pharmaceuticals, Inc. has a 52-week low of $25.53 and a 52-week high of $40.28. The stock's fifty day simple moving average is $31.94 and its two-hundred day simple moving average is $34.60. The firm has a market capitalization of $1.78 billion, a P/E ratio of 29.71 and a beta of 0.74.

Analyst Ratings Changes

A number of research firms have issued reports on SUPN. Wall Street Zen raised Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday, May 16th. Cantor Fitzgerald reiterated a "neutral" rating and set a $36.00 target price on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.